0 التعليقات
0 المشاركات
799 مشاهدة
0 معاينة
الدليل
إكتشاف أشخاص جدد وإنشاء اتصالات جديدة وصداقات جديدة
-
الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!
-
0 التعليقات 0 المشاركات 261 مشاهدة 0 معاينة
-
HSBC starts Constellation Energy (CEG) and Vistra (VST) at buy and models $14 billion of buybacks at eachHSBC began coverage of Constellation Energy Corporation (CEG) at buy with a $335 target and Vistra Corp. (VST) at buy with a $190 target, forecasting earnings per share growth of 19% and 21% a year to 2030. HSBC has opened coverage of two of the largest US power generators with buy ratings. It set a $335 target on Constellation Energy Corporation (CEG) and a $190 target on Vistra Corp. (VST)....0 التعليقات 0 المشاركات 970 مشاهدة 0 معاينة
-
0 التعليقات 0 المشاركات 261 مشاهدة 0 معاينة
-
STMicroelectronics kept buying back shares as its price fellSTMicroelectronics spent EUR 17.1 million buying 346,538 shares in the week to October 9. Daily purchases rose as the share price fell. Trend & Ticker breaks down the pace. STMicroelectronics N.V. (STM) published its latest share buyback update on October 12. The release covers trading from October 5 to October 9, 2026. The chipmaker bought 346,538 ordinary shares in that window, equal to...0 التعليقات 0 المشاركات 558 مشاهدة 0 معاينة
-
0 التعليقات 0 المشاركات 91 مشاهدة 0 معاينة
-
0 التعليقات 0 المشاركات 302 مشاهدة 0 معاينة
-
ServisFirst (SFBS) earns 80 cents a share, 3 cents short of forecasts, as loans outgrow depositsServisFirst Bancshares Inc. lifted third-quarter profit 33% from a year earlier and held its margin at 3.63%, but deposits fell $461 million while loans kept growing. ServisFirst Bancshares Inc. (SFBS) ended September lending about $1.05 for every $1.00 of deposits, as calculated by Trend & Ticker from the Birmingham, Alabama bank's October 19 earnings release. Deposits fell $461 million...0 التعليقات 0 المشاركات 870 مشاهدة 0 معاينة
-
0 التعليقات 0 المشاركات 327 مشاهدة 0 معاينة
-
Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in EuropeAlvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...0 التعليقات 0 المشاركات 1كيلو بايت مشاهدة 0 معاينة